Its oral drug o rforglipron , currently in phase 3 trials for obesity and T2D, is a daily oral GLP-1 that could appeal to patients that prefer not to inject themselves, as well as for patients that are located in geographies that lack the necessary cold chain infrastructure to adequately transport and store the injectables
MATERIALS AND METHODS The current study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension statement for the reporting of systematic reviews incorporating NMAs of Health Care Interventions (Supplementary Material 10) [28]
Liang X, Fu Y, Cao W-t, Wang Z, Zhang K, Jiang Z, et al
Today, studies estimate that over 80 percent of the personalized compounded GLP-1 drugs now being marketed include added ingredients such as B vitamins (B6, B12, B3)